

**CANCER FUND Invests in Avesta76 Therapeutics, Inc., A Novel Approach to Cancer Treatment**

*Avesta76 is pioneering a new therapeutic with curative and preventative potential for multiple cancers including ovarian (initial target), breast, and esophageal.*

**Phoenix, AZ, November 06, 2023** – CANCER FUND announces its investment in Avesta76, a cancer therapeutics company developing a novel platform for multiple cancers. The investment represents CANCER FUND's fifth investment out of Cancer Fund I. It becomes its fourth portfolio company in pursuit of its mission to support cancer innovators' advance from the lab to patient care.

"We are thrilled to support Avesta76 and add them to our investment portfolio. Early indications show their focused therapeutics offer promise for multiple cancers of interest to our investor community, including chemo-resistant ovarian, breast (specifically Triple Negative Breast Cancer), and colo-rectal among others. Avesta76 is breaking new ground and showing promising early animal testing data indicating efficacy in both tumor prevention and regression. We believe it may offer a new therapeutic alternative for patients who have developed chemo-resistance to current treatments, saving lives and improving patient survival," said CANCER FUND Managing Director Anthony Bajoras.

"Avesta76 is excited to add Cancer Fund I as an investor and long-term partner. We've built a strong relationship with the CANCER FUND team and value both their mission of supporting innovative oncology-focused companies on the path to reach patients, and their unique community-driven investment model," said Avesta76 Therapeutics Co-Founder & CEO Akash Morrison.

**About CANCER FUND:**

CANCER FUND is a community of impact investors committed to advancing cancer care, fostering innovative solutions, and enhancing the lives of cancer patients, survivors, and previvors. Through collaboration with a diverse community of over 2,300 members, including patients, survivors, caregivers, healthcare professionals, and impact investors, CANCER FUND is currently investing out of Cancer Fund I, dedicated to driving significant change in the fight against cancer. To learn more about how you can become part of our investor community, visit [www.cancerfund.com](http://www.cancerfund.com).

**About Avesta76 Therapeutics, Inc.:**

"Avesta76 is developing a therapy focused on commonalities of cancer cells and the role oxidative stress plays in disease. Through decades of research, they have identified and isolated a target that plays a crucial role in cancer survival. Many cancers act to significantly upregulate this target, aiding cancer cells to both survive and proliferate. Avesta76's novel therapeutics may effectively turn off one of cancer's "Master Switches". If successful, it might help patients that have become therapy resistant and play a role in the prevention for some genetically predisposed previvors. To learn more about Avesta76, visit [www.avesta76.com](http://www.avesta76.com)

**Disclaimer**

Contents of this release are provided for general information purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any security of CANCER FUND or its affiliates in any jurisdiction. CANCER FUND does not intend to solicit and IS not soliciting, any action with respect to any Security or any other contractual relationship. Nothing in this release or the contents thereof, individually or taken in the aggregate, constitutes an offer of securities for sale or a solicitation of an offer to buy any security in the United States or in any other jurisdiction in which such an offer or solicitation is unlawful.

**Forward Looking Statements**When used herein, the words “anticipate”, “believe”, “could”, “estimate”, “expect”, “going forward”, “intend”, “may”, “ought to”, “plan”, “project”, “seek”, “should”, “will”, “would” and similar expressions, as they relate to CANCER FUND, CANCER FUND affiliates including Cancer Fund I, LLC, CANCER FUND’s management, or any of their actual or prospective investments, are intended to identify forward-looking statements. These forward-looking statements reflect CANCER FUND’s views at the time such statements were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known,-unknown, and unknowable risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules and regulations relating to any aspects of-CANCER FUND’s or its affiliates business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, various business opportunities that CANCER FUND may or may not pursue, changes in population growth and other demographic trends, including mortality, morbidity and longevity rates, persistency levels, CANCER FUND’s ability to identify, measure, monitor and control risks in CANCER FUND’s business, including its ability to manage and adapt its overall risk profile and risk management practices, and seasonal fluctuations and factors beyond CANCER FUND’s control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. CANCER FUND undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.